How to control chlamydia – an ECDC guidance for Europe
They are young and mostly female: with more than 3.2 million cases between 2005 and 2014, chlamydia remains the most commonly reported sexually transmitted infection (STI) across Europe. The updated ECDC guidance on chlamydia control in Europe makes the case for national chlamydia control strategies in the EU Member States and shows ways to develop, implement or improve national or local control activities.
Five infectious diseases accounted for 75% of reported cases in EU - summary report
Chlamydia infection, campylobacteriosis, salmonellosis, gonorrhoea and tuberculosis were the most commonly reported notifiable infectious diseases in the EU and EEA in 2014.
Chlamydia on the rise in Europe: new ECDC report on sexually transmitted infectionsArchived
They are young, mostly female and their number is constantly growing: with nearly 344 000 notified cases in 2009 chlamydia is the most frequently reported sexually transmitted infection (STI) across Europe.
31st Congress of IUSTI-Europe on Sexually Transmitted Infections
The 31st IUSTI (International Union Against Sexually Transmitted Infections) Europe Congress addressed the broad range of science and clinical practice in the field of sexually transmitted infections.
Gonorrhoea strains across Europe becoming more susceptible to main treatment options
According to test results from the annual European Gonococcal Antimicrobial Surveillance Programme (Euro-GASP), resistance levels to the main antimicrobials used for treatment of gonorrhoea infection have seen an encouraging decrease since 2010.
ECDC: first detected cases of extensively drug-resistant gonorrhoea threaten future treatment
Within a matter of weeks, three cases of gonorrhoea that are resistant to the recommended first line antibiotic treatment have been detected in Europe and Australia. These are the first global reports of Neisseria gonorrhoeae with high-level resistance to azithromycin and ceftriaxone resistance that also show resistance to several other vital antibiotics. At a time with limited alternatives to the current dual therapy, lack of a vaccine and insufficient surveillance capacity in some regions, these cases highlight the growing threat of drug-resistance – which could lead to untreatable gonorrhoea.
Understanding drug-resistant gonorrhoea: an ECDC whole genome sequencing study
Can whole genome sequencing illustrate changes in drug susceptibility of gonorrhoea to antimicrobials used for treatment and so help to define more effective treatment regimens? The first study of this kind within an international surveillance programme for sexually transmitted infections shows distribution of drug-resistant gonorrhoea strains across Europe.
Drug-resistance of gonorrhoea in the EU: persistent but stable
Neisseria gonorrhoea continues to show high levels of resistance to azithromycin across the European Union and European Economic Area, according to the 2016 results of the European Gonococcal Antimicrobial Surveillance Programme (Euro-GASP).
Call for scientific collaboration to support genomic-based surveillance of Neisseria gonorrhoeae-antimicrobial resistance at EU-level
ECDC is looking to establish a scientific collaboration with an organisation which can perform whole genome sequencing (WGS) of Neisseria gonorrhoeae, carry out related data analyses, share results of the analyses with ECDC and the participants of the European Gonococcal Antimicrobial Surveillance Programme as well as visualise the results.